Phase III results revealed today at The International Liver Congress™
2015 show that once-daily treatment with daclatasvir (DCV) plus
sofosbuvir (SOF) resulted in an overall 97% sustained virologic response
(SVR) at 12 weeks post-treatment in patients with hepatitis C virus
(HCV) and HIV co-infection, including cirrhotic patients.
HIV co-infection more than triples the risk of hepatitis C-related
liver disease, liver failure and liver-related death. Co-infection can
also complicate the management of HIV infection.
In the ALLY-2 randomised, open-label study, the combination of
DCV+SOF was well tolerated and effective across the four different
genotypes. Importantly, due to their limited pharmacokinetic
interactions with other agents, DCV+SOF was able to work effectively
across a broad range of concomitant combination antiretroviral therapy
(cART) regimens without compromising HIV virologic control (98% of
patients were on cART).
Labels: daclatasvir plus sofosbuvir, HIV-HCV coinfection